AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Castle Biosciences Inc. (CSTL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

26.14

-1.05 (-3.86%)

At close: Feb 20, 2025, 3:59 PM

26.15

0.04%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	24.1
Market Cap	732.11M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	0.21
PE Ratio (ttm)	124.48
Forward PE	n/a
Analyst	Buy

Ask	28.5
Volume	278,543
Avg. Volume (20D)	377,384
Open	27.05
Previous Close	27.19
Day's Range	25.91 - 27.10
52-Week Range	16.96 - 35.84
Beta	undefined

About CSTL

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients w...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Jul 25, 2019

Employees 710

Stock Exchange NASDAQ

Ticker Symbol CSTL

Website https://castlebiosciences.com

Full Company Profile

Analyst Forecast

According to 7 analyst ratings, the average rating for CSTL stock is "Buy." The 12-month stock price forecast is $40.5, which is an increase of 54.93% from the latest price.

Buy 85.71%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Castle Biosciences Inc. is scheduled to release its earnings on Feb 27, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

-13.55%

Castle Biosciences shares are trading lower after ... Unlock content with Pro Subscription

4 months ago

+9.42%

Castle Biosciences shares are trading higher after BTIG maintained a Buy rating on the stock and raised its price target from $35 to $40.

News

13 hours ago · zacks.com

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

14 hours ago · zacks.com

Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 50.8% in Castle Biosciences (CSTL). While the effectiveness of this highly sought-after metric is questionable,...

1 week ago · businesswire.com

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of GEP tests at the 2025 Winter Clinical Dermatology Conference - Hawaii,...

1 week ago · zacks.com

Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock

Castle Biosciences (CSTL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

1 week ago · zacks.com

Castle Biosciences (CSTL) Upgraded to Buy: Here's Why

Castle Biosciences (CSTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3 weeks ago · zacks.com

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

The mean of analysts' price targets for Castle Biosciences (CSTL) points to a 51.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amo...

4 weeks ago · zacks.com

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Buy these four top-ranked stocks, CSTL, OPFI, GCT and QIFU, with solid net profit margins to enhance your portfolio returns.

1 month ago · businesswire.com

Castle's Poster on DecisionDx®-SCC Selected as a “Late Breakers” Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will share data supporting its dermatologic portfolio of tests for skin cancer through poster presentations at the Maui Derm Ha...

1 month ago · businesswire.com

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary...

1 month ago · businesswire.com

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus Test

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Barrettsesophagus--Castle Biosciences has received assay approval from the New York State Department of Health (NYSDOH) for its TissueCypher Barrett's Es...

Load More News